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Objective: This study was undertaken to investigate whether infection of a vascular graft with Staphylococcus aureus can be
treated in situ by applying antibiotic-loaded porous apatite ceramic, in a rabbit model.
Methods: Teicoplanin (TEIC) was loaded onto a -tricalcium phosphate (TCP) block, a type of porous apatite ceramic.
The activity of TEIC released from the antibiotic-loaded TCP block was examined in vivo. A vascular graft was patched
onto the abdominal aorta in 24 rabbits, and S aureus was applied directly on it. Seven days postoperatively, each rabbit
underwent repeat laparotomy, and retroperitoneal abscess around the prosthetic vascular patch was debrided. Animals
were divided into four groups of 6 rabbits each. In group 1 only debridement was carried out. In groups 2 and 3, solution
containing 40 or 60 mg of TEIC, respectively, was applied to the prosthetic vascular patch. In group 4, an antibiotic-
loaded TCP block (63 6.6 mg of TEIC) was placed around the graft. Three weeks after the second operation, the graft,
the tissue around it, and arterial blood were collected and cultured.
Results: TEIC activity was maintained for 28 days in vivo. In group 1, bacterial cultures of the prosthetic vascular graft
and the tissue around it were positive in 5 animals and negative in 1 animal (infection rate, 83%). In both groups 2 and
3, cultures were positive in 3 animals and negative in 3 animals (infection rate, 50%). In group 4, cultures were negative
in all animals (infection rate, 0%). Blood cultures were negative in all animals. Infection rate in group 4 was significantly
lower than that in group 1 (P  .03), and was also lower than that in groups 2 and 3, but the difference was not
significant.
Conclusions: Use of slow-release antibiotic loaded onto a TCP block, along with debridement, may control infection in
vascular grafts in situ, averting the necessity to remove the graft. (J Vasc Surg 2003;38:368-73.)
Prosthetic vascular graft infection is a serious complica-
tion of vascular surgery, despite its low incidence of 1.3% to
2.6% in reports published in the 1990s.1,2
Prosthetic vascular graft infection has been treated with
removal of the infected graft followed by conventional
extra-anatomic bypass grafting3,4 or, in recent years, with in
situ repair with rifampicin-bonded prosthetic vascular
grafts5 or cryopreserved homografts.6 However, these pro-
cedures require removal of the infected prosthetic vascular
graft.
In addition to simple local antibiotic administration,
multivesicular liposome-encapsulated amikacin,7 biode-
gradable amikacinmicrospheres,8 gentamicin with collagen
sponge,9,10 and gentamicin beads11,12 have been used as
drug delivery systems.
In addition, clinical application of a slow drug-release
system with a porous hydroxyapatite block has been re-
ported in treatment of intractable osteomyelitis.13,14
We reported that an antibiotic-releasing system, ie,
teicoplanin (TEIC) antibiotic applied to a porous apatite
ceramic (-tricalcium phosphate [TCP]) block, is useful in
preventing intraoperative graft infection with Staphylococ-
cus aureus during graft replacement.15 The purpose of this
experiment was to determine whether this slow-release
system can control infection without removal of the pros-
thetic vascular graft.
MATERIALS AND METHODS
Materials. S aureus (Gifu 12173) was used as the
infecting organism. The S aureus strain was obtained from
a patient at Gifu University Hospital and was sensitive to
penicillin and methicillin. It was incubated overnight on
sheep blood agar. Numbers of bacteria were determined
with turbidimetry and confirmed with culture results.
The antibiotic used was teicoplanin (TEIC; Aventis
Pharma SA, Frankfurt, Germany).16
TCP (Ca3[PO4]2; Olympus, Tokyo, Japan) had the
following properties: porosity, 75%; pore size, 100 to 400
m; average weight, 0.44 g; and arch shape, with 14 mm
outside diameter, 5 mm inside diameter, and 10 mm
height. With this TCP as a carrier, a sustained-release test
and an animal experiment were carried out.
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Gelatin-sealed knittedDacron (Gelseal; Vascutek, Ren-
frewshire, England) was used as an elliptical patch, measur-
ing 5  3 mm.
Male Japanese White rabbits (2.5 kg; Chubu Kagaku
Shizai, Nagoya, Japan) were used.
Methods. Minimum inhibitory concentration (MIC)
of TEIC for S aureus strain was examined with the E test17
(Asuka Junyaku, Tokyo, Japan).
TCP was prepared with the vacuum method, as de-
scribed by Itokazu et al.18 TCP, weighing 0.44 g on
average, was immersed in 5.5 mL of TEIC solution (180
mg/mL) under negative pressure of 254 mm Hg for 20
minutes in a decompression chamber. TEIC content in
TCP was calculated as weight increase.19
Each rabbit (2.5 kg) was anesthetized with 0.6 mL/kg
of ketamine hydrochloride administered intramuscularly.
Endotracheal tubes were placed, and the rabbits were po-
sitioned supine after sterilization of the abdominal wall. All
rabbits received mechanical ventilation. Anesthesia was
maintained intravenously with 0.6 mg/kg of pentobarbi-
turate sodium chloride and 0.8 mg/kg of pancuronium
bromide. After laparotomy, antibiotic-loaded TCP was
placed in the retroperitoneal space.
The rabbits were killed on day 3, 7, 14, 21, or 28. TCP
was removed and stored in 2 mL of fresh saline solution in
a constant temperature bath at 37°C. The concentration of
TEIC released from TCP into the saline solution was
measured with a fluorescence polarization immunoassay
(FPIA).20 Minimal concentration of released TEIC mea-
sured with FPIA was 4 g/mL. TEIC concentration less
than 4 mg/mL was measured with a bioassay.21
Twenty-four rabbits were used in this study. The aorta
was approached transperitoneally through a mid-abdomi-
nal incision. The aorta was cross-clamped above and below
the patch-suturing region, and a 5  3 mm graft was
patched on the anterior wall of the abdominal aorta with
6/0 polypropylene suture. Bacterial suspension containing
2 107 colony-forming units was directly applied on the
prosthetic vascular graft after suturing, and the posterior
peritoneum was closed with sutures. Seven days after the
first operation, each rabbit underwent repeat laparotomy
and debridement of the retroperitoneal abscess surround-
ing the graft (Fig 1, A, B). Heparin and antibiotics were
not administrated systemically in this experiment.
Animals were divided into 4 groups with 6 rabbits each
(Table I): group 1, debridement only; group 2, after de-
bridement, solution containing 40mg of TEICwas applied
to the prosthetic vascular patch; group 3, after debride-
ment, solution containing 60 mg of TEIC was applied to
the prosthetic vascular patch; and group 4, after debride-
ment, antibiotic-loaded TCP was placed straddling the
patch graft (Fig 1, C).
After these procedures, the posterior peritoneum was
closed with sutures.
All animal care complied with the Principles of Labo-
ratory Animal Care and the Guide for the Care and Use of
Laboratory Animals (NIH Publication No. 80-23, revised
1985).
Fig 1. Infected graft. A, Retroperitoneal abscess around patch
graft (arrow) on day 7. B, Patch graft (arrow) after debridement of
infected tissue. C, After debridement, antibiotic-loaded -trical-
cium phosphate block (arrow) was placed straddling the patch
graft.
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Twenty-one days after the second operation (debride-
ment), the prosthetic vascular graft, tissue around it, and
arterial blood were collected. Each specimen of prosthetic
vascular graft and surrounding tissue was placed in liquid
medium (heart infusion broth, 2 mL) and stirred with an
automatic mixer for 1 minute. After incubation at 37°C
under 5% CO2 for 6 hours, 100 L of heart infusion broth
was directly inoculated over sheep blood agar (selection
medium for bacteria in general) and mannitol salt agar
(selection medium for S aureus). Arterial blood, 100 L
was similarly inoculated. Each agar sample was incubated at
37°C under 5%CO2 for 48 hours for aerobic culture.When
colonies were found on both sheep blood agar and manni-
tol salt agar, the culture was judged as positive.
When group 4 rabbits were killed, TCP was removed
and stored in 2 mL of fresh saline solution and placed in a
constant temperature bath at 37°C. The concentration of
TEIC released from TCP into the saline solution was
measured with FPIA.
Statistical analysis. Data were analyzed with analysis
of variance and the Sheffe test. P  .05 was considered
significant.
RESULTS
MIC for TEIC for S aureus was 1.5 g/mL.
TCP with an initial weight of 0.44 g contained 53.8 to
73.8 mg (mean, 63.6  6.6 mg) of TEIC.
With FPIA, concentration of TEIC on day 3 was 33.2
g/mL, on day 7 was 24.7 g/mL, and on day 14 was
15.1g/mL.With bioassay, concentration of TEIC on day
21 was 1.23 g/mL, and on day 28 was 1.61 g/mL.
Although TEIC concentration on day 21 was 1.23 g/
mL, that on day 28 was higher than MIC (Fig 2).
Seven days after implantation of the prosthetic vascular
graft on the abdominal aorta, retroperitoneal abscess
around the prosthetic vascular patch was observed (Fig 1,
A), and cultures were positive for bacteria in all animals.
In group 1, 1 rabbit died of anastomotic disruption on
day 9 after the second operation (debridement); all other
animals in all groups survived for 4 weeks until they were
killed.
Blood cultures were negative in all rabbits.
In group 1, bacterial cultures of the prosthetic vascular
graft and surrounding tissue were positive in 5 animals and
negative in 1 animal. The infection rate was 83%, including
the 1 animal that died of anastomotic disruption, in which
bacteriologic culture of the abscess was positive. In both
groups 2 and 3, bacterial cultures were positive in 3 animals
and negative in the other 3 animals. In group 4, bacterial
cultures of the prosthetic vascular graft and surrounding
tissue were negative in all animals. The infection rate in
group 2 was 50%, in group 3 was 50%, and in group 4 was
0% (Table II). The infection rate in group 4 was signifi-
cantly lower than that in group 1 (P  .03), and also was
lower than that in groups 2 and 3, but the difference was
not significant.
In group 4, TEIC concentration in 3 rabbits when
killed was 28.5, 7.9, and 5.5 g/mL. In 3 other rabbits it
was below detection threshold with FPIA (4 g/mL);
bioassay was not performed in these 3 animals. Residual
TEIC in TCP in at least 3 rabbits was higher than MIC,
demonstrating the slow-release capability of TCP in this
study.
DISCUSSION
Prosthetic vascular graft infection is one of the serious
complications of vascular surgery. Conventionally, pros-
thetic vascular graft infection has been treated by removal
of the infected graft followed by extra-anatomic bypass
grafting3,4 or anatomic reconstruction.5,6,22 Extra-ana-
tomic bypass grafting has a lower patency rate than ana-
tomic reconstruction23 and is complicated by aortic stump
blowout.24-26 Anatomic reconstruction as in situ repair has
been associated with graft reinfection in 14% to 22% of
cases22,27 and rupture of anastomoses in 11% to 28% of
cases.27,28
Other approaches used in an attempt to prevent rein-
fection include replacement with cryopreserved ho-
mografts,6 which are reportedly more resistant to infection
than prosthetic vascular grafts are. However, homografts
are difficult to obtain.
It would be ideal if graft infection could be controlled
without removal of the infected graft, such as with perigraft
packing with pedicled muscle flaps,29,30 omental transpo-
sition,31,32 and packing with povidone iodine sponges.32
Calligaro et al33 recommended graft-preserving therapy,
primarily with debridement, in patients who meet three
criteria: patent graft, intact anastomosis, and absence of
systemic sepsis. They reported in-hospital mortality of 10%
and limb amputation rate of 3% with this procedure. An-
other study reported that graft-preserving treatment was
effective in infections occurring early after surgery.34
Several studies have used local antibiotic irrigation in an
attempt to prevent prosthetic vascular graft infection.35-38
Performing continuous antibiotic irrigation of major aortic
graft infection, Morris et al35 achieved a 1-year survival rate
of 80% and a 4-year survival rate of 67%. Irrigation therapy
was performed for a mean of 23 days (range, 12-56 days).35
Table I. Study groups
Group Baseline* Week 1 Week 4
1 Patch graft  SA Debridement Sacrifice
2 Patch graft  SA Debridement 
40 mg TEIC
Sacrifice
3 Patch graft  SA Debridement 
60 mg TEIC
Sacrifice
4 Patch graft  SA Debridement 
antibiotic-
loaded TCP
block
Sacrifice
SA, Staphylococcus aureus; TEIC, teicoplanin; TCP, -tricalcium phosphate
block.
*At baseline, patch grafts were placed in all animals and S aureus was applied
directly on it.
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Another attempt to control prosthetic vascular graft
infection used a system that slowly releases a high concen-
tration of antibiotics locally for long periods. The problems
with these systems are the duration of effective concentra-
tions and tissue reaction to drug carriers.
Multivesicular liposomes,7 biodegradable micro-
spheres,8 and collagen sponges9,10 were also effective. Ri-
fampicin-impregnated, gelatin-sealed,39 or collagen-
sealed40 Dacron grafts show a slow-releasing effect.
However, the duration of effective concentration of antibi-
otics from these slow-releasing systems is relatively short,
up to 22 days.40 The disadvantage of gentamycin beads is
that they must later be removed as foreign bodies.11,12
Similar to prosthetic vascular graft infection, osteomy-
elitis is intractable. Studies have reported drug-release sys-
tems with antibiotic-loaded porous hydroxyapatite
blocks.13,14 Using an in vitro drug-releasing system con-
sisting of an antibiotic-loaded hydroxyapatite block to treat
Fig 2. In vivo study showed that teicoplanin (TEIC) concentration in replaced saline solution remained above
minimum inhibitory concentration for Staphylococcus aureus for 28 days.
Table II. Infection rate
Group
No. of
rabbits
Bacteriologically positive (%)
Graft Tissue Blood
n % n % n %
1: Control 6* 5 83
†
5 83
†
0 0
2: 40 mg TEIC 6 3 50 3 50 0 0
3: 60 mg TEIC 6 3 50 3 50 0 0
4: TEIC-loaded TCP 6 0 0 0 0 0 0
TEIC, Teicoplanin; TCP, -tricalcium phosphate.
*Includes graft with anastomotic disruption.
†P  .03, group 4 vs group 1.
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osteomyelitis, Itokazu et al14 confirmed slow release of the
antibiotic over approximately 40 daysd,14 and reported that
all 7 patients recovered from osteomyelitis.13
However, compared with hydroxyapatite, TCP is a new
porous apatite ceramic with better tissue compatibility.41
Compared with hydroxyapatite, TCP enables loading of a
larger amount of drug because of its higher porosity, result-
ing in longer, slower drug release.42
TEIC-loaded TCP is useful in preventing graft infec-
tion with S aureus.15 Thus, in this study, we selected TCP
as a slow drug- releasing carrier, and investigated whether it
could be useful for local treatment of infected graft in situ.
Our system with TCP had a slow-releasing effect over
40 days in vitro, as Sago et al15 previously reported. In this
study, drug release lasted 28 days in vivo, longer than
reported previously.40 In group 4, the residual amount of
TEIC in TCP in 3 rabbits at least remained above MIC,
confirming the slow-release capability of TCP.
The rifampin-bonding Dacron graft was specific with
collagen and rifampin interrelation, which limited selection
of antibiotics to rifampin thus far.43 In clinical practice, one
advantage of our system with TCP is the ability to select
from a wide range of antibiotics to be loaded.
Replacement of an infected vascular graft is difficult
because of infection-induced fragility of tissue at the anas-
tomosis. However, our procedure requires only debride-
ment of the abscess, followed by placement of TCP.
Pedicled muscle flaps29,30 and omental transposi-
tion31,32 are highly effective, but their use is limited by
location, eg, the groin and some parts of the abdomen and
chest, respectively. However, our system with TCP is not
limited by location or area to be covered.
In this experiment, group 2 was designed to test ad-
ministration of a dose equivalent to intravenous injection
per kilogram of body weight for systemic administra-
tion,44-47 and group 3 involved a dose similar to that
loaded in the TCP block. Although we could not find any
significant differences between group 4 and groups 2 or 3,
infection rates in groups 2 and 3 were 50%. In contrast, the
infection was successfully controlled without removal of the
infected vascular graft in all groups in which TEIC-loaded
TCP was used.
These results suggest that a single local dose of antibi-
otic may be insufficient for control of prosthetic vascular
graft infection without removal of the already infected
graft. However, prolonged release of effective concentra-
tions of antibiotics at the site of infection is sufficient to
treat the graft without removal.
In this experiment, we did not investigate whether TCP
would become a foreign body and a new source of infec-
tion. Although biodegradation of TCP might take a long
time, TCP in bone is biodegradable.48 TCP has high
biocompability.41 There have been no reports that TCP
remaining in the body causes reinfection.
In summary, use of a slow-release system with antibi-
otic-loaded TCP and debridement may be used to control
graft infection in situ.
We thank Prof Dr Takayuki Esaki, Department of
Microbiology, Gifu University School of Medicine, for the
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